Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML.
Liu TW, et al. Among authors: huang cf, huang jf, huang ci.
J Formos Med Assoc. 2018 Jan;117(1):54-62. doi: 10.1016/j.jfma.2017.02.013. Epub 2017 Apr 4.
J Formos Med Assoc. 2018.
PMID: 28389143
Free article.